Abstract
There has been a significant increase in the number of cytokines known to exist, over the past few years. This has led to a re-examination of the established roles of cytokines, as the functions of newly identified members are characterized. In this review, we describe how the recent discovery and characterization of interleukin (IL) -23 has led to a re-evaluation of the role of interferon (IFN) γ and IFNγ-inducing factors in experimental autoimmune encephalomyelitis (EAE). Recent studies suggest that IFNg-secreting T cells, considered the hallmark of EAE, may not be the major detrimental effector cell, and may even have a regulatory function. The impact of this on current understanding of cytokine networks underlying CNS inflammation in EAE is discussed.
Keywords: interferon gamma, interleukin 23, experimental autoimmune encephalomyelitis
Current Pharmaceutical Design
Title: The Changing Face of Cytokines in the Brain: Perspectives From EAE
Volume: 11 Issue: 8
Author(s): R. D. Wheeler and T. Owens
Affiliation:
Keywords: interferon gamma, interleukin 23, experimental autoimmune encephalomyelitis
Abstract: There has been a significant increase in the number of cytokines known to exist, over the past few years. This has led to a re-examination of the established roles of cytokines, as the functions of newly identified members are characterized. In this review, we describe how the recent discovery and characterization of interleukin (IL) -23 has led to a re-evaluation of the role of interferon (IFN) γ and IFNγ-inducing factors in experimental autoimmune encephalomyelitis (EAE). Recent studies suggest that IFNg-secreting T cells, considered the hallmark of EAE, may not be the major detrimental effector cell, and may even have a regulatory function. The impact of this on current understanding of cytokine networks underlying CNS inflammation in EAE is discussed.
Export Options
About this article
Cite this article as:
Wheeler D. R. and Owens T., The Changing Face of Cytokines in the Brain: Perspectives From EAE, Current Pharmaceutical Design 2005; 11 (8) . https://dx.doi.org/10.2174/1381612053381657
DOI https://dx.doi.org/10.2174/1381612053381657 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Defining Peptide Sequences: From Antigenicity to Immunogenicity Through Redundancy
Current Pharmacogenomics Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Glucocorticoid Analogues: Potential Therapeutic Alternatives for Treating Inflammatory Muscle Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Medicinal Chemistry of Therapeutic Peptides: Recent Developments in Synthesis and Design Optimizations
Current Medicinal Chemistry CCR1 and CCR2 Antagonists
Current Topics in Medicinal Chemistry Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier
Current Pharmaceutical Design Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Possible Pathomechanisms Responsible for Injury to the Central Nervous System in the Settings of Chronic Cerebrospinal Venous Insufficiency
Reviews on Recent Clinical Trials Advances in Design and Development of Inhibitors of Nitric Oxide Synthases
Current Enzyme Inhibition Editorial [ Advances in Heme Oxygenase Research as a Potential Therapeutic Strategy Executive Editor: M.J. Alcaraz]
Current Pharmaceutical Design CD147: A Novel Modulator of Inflammatory and Immune Disorders
Current Medicinal Chemistry Temporal Progression of Kainic Acid Induced Changes in Vascular Laminin Expression in Rat Brain with Neuronal and Glial Correlates
Current Neurovascular Research Therapeutic Interventions of Tissue Specific Autoimmune Onset in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry Making the Animal Model for AIDS Research More Precise: The Impact of Major Histocompatibility Complex (MHC) Genes on Pathogenesis and Disease Progression in SIV-Infected Monkeys
Current Molecular Medicine Pericyte: Potential Target for Hemorrhagic Stroke Prevention and Treatment
Current Drug Delivery Therapeutic Potential of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors for the Treatment of Retinal and Eye Diseases
CNS & Neurological Disorders - Drug Targets Antiviral Role of Toll-Like Receptor-3 Agonists Against Seasonal and Avian Influenza Viruses
Current Pharmaceutical Design Advances in Antioxidative Therapy of Multiple Sclerosis
Current Medicinal Chemistry Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design